Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : JPMorgan, Goldman Sachs delay workers' return to U.K. offices

06/16/2021 | 04:57pm EDT
FILE PHOTO: FILE PHOTO: COVID-19 surge testing site in London

NEW YORK (Reuters) - Global banks JPMorgan Chase & Co and Goldman Sachs are delaying plans for workers to return to U.K. offices after the government extended its COVID-19 restrictions until mid-July due to the rapid spread of the more infectious Delta variant.

Goldman Sachs Group Inc, which required most U.S. staff to return to offices this week, told U.K. staff on Tuesday that working at its London office will remain voluntary for now, according to a memo seen by Reuters. Social distancing and mask-wearing is required, while the broader return to office plans are postponed until July, the bank said.

JPMorgan Chase & Co, which is requiring the majority of U.S. staff to return next month, notified U.K.-based employees that its broad return-to-office plans are on hold until July, according a memo to its staff.

The investment banks had planned to bring more staff back to offices--on a rotational basis, subject to a 50% occupancy cap--on some of the quickest timelines.

For both banks, roughly 20-30% of staff had been working in offices for several months, which allowed them to work out social distancing and health check protocols.

But the U.K. said delaying full reopening until July 19 will allow it to get more people fully vaccinated. Currently, about 41 million people have received their first shot and nearly 30 million have had both doses - about 57% of the adult population.

The majority of Goldman Sachs employees have "either had their first dose (of the vaccine) or expect to receive it before Monday, 21 June," Richard Gnodde, head of Goldman Sachs International, wrote in his memo to staff.

Studies on Monday showed the Delta variant doubles the risk of hospitalization, but two doses of vaccines made by Pfizer and AstraZeneca offer more than 90% protection against hospitalization.

(Reporting by Elizabeth Dilts Marshall; editing by Diane Craft)

By Elizabeth Dilts Marshall

ę Reuters 2021
All news about ASTRAZENECA PLC
12:33pASTRAZENECA : SVB Leerink Adjusts Price Target on AstraZeneca to $69 From $63, M..
08:38aASTRAZENECA : Japan to ship total of 1.6 mil. COVID vaccine doses to Nepal
03:10aThai hospital tycoon who promised Pfizer vaccine says deal now unlikely
08/03ASTRAZENECA : Chilean study shows variations in success of COVID-19 vaccines
08/03THE LATEST : NYC: Vaccination proof for indoor dining, gyms
08/03ASTRAZENECA : SAPHNELO approved in the US for moderate to severe systemic lupus ..
08/03ASTRAZENECA : Sanwo-Olu - Lagos Recorded 4,300 Cases, 30 Fatalities in July
08/03ASTRAZENECA : Covid-19 Third Wave - Lagos Records 42 Deaths in One Week - Sanwo-..
08/02Fancy a Covid jab? Here are all the free walk-in sites open in London
08/02U.S. Food and Drug Administration Approves AstraZeneca PLC's SaphneloÖ (Anifr..
More news
Financials (USD)
Sales 2021 35 164 M - -
Net income 2021 5 236 M - -
Net Debt 2021 25 946 M - -
P/E ratio 2021 30,5x
Yield 2021 2,44%
Capitalization 178 B 178 B -
EV / Sales 2021 5,81x
EV / Sales 2022 4,71x
Nbr of Employees 76 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 29
Last Close Price 115,47 $
Average target price 133,83 $
Spread / Average Target 15,9%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC13.29%178 598
JOHNSON & JOHNSON10.81%459 079
ROCHE HOLDING AG14.16%340 492
PFIZER, INC.24.10%255 703
NOVARTIS AG-0.20%224 638